Although CDN’s potential in CRC was suggested by a study showing its efficacy in a colitis—associated model via suppression of NF-κB and iNOS (James et al., 2021), its direct targeting of the JAK/STAT3 axis—a key driver of CRC-remains largely unexplored. The gene discussed is NFKB1; the disease is colorectal carcinoma.